Dr. Reddy’s Laboratories Ltd. has received a Form 483 containing two observations from the US Food and Drug Administration following an inspection of its FTO-11 manufacturing facility at Pydibhimavaram in Andhra Pradesh. The inspection took place from October 5 to October 7, 2026.
A Form 483 is issued by the US regulator when inspectors identify conditions that may violate regulatory requirements. The observations are not, by themselves, a final determination that the facility is non-compliant, and the company’s response and any subsequent regulatory action will be important to monitor.
The development has placed the pharmaceutical company under investor scrutiny as the market assesses potential implications for manufacturing operations and product approvals. The eventual impact will depend on the nature of the observations and the corrective measures undertaken by the company.
